Catalyst Pharmaceuticals, Inc. (CPRX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Coral Gables, FL, United States. El CEO actual es Richard John Daly.
CPRX tiene fecha de IPO 2006-11-08, 181 empleados a tiempo completo, cotiza en el NASDAQ Capital Marke, una capitalización de mercado de $3.22B.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company headquartered in Coral Gables, Florida, specializing in therapies for rare neuromuscular and neurological diseases. The company's primary product, Firdapse (amifampridine phosphate), is approved for treating Lambert-Eaton Myasthenic Syndrome (LEMS) in adults, while its pediatric formulation, Ruzurgi, addresses LEMS in children. Catalyst is advancing Firdapse through clinical development for additional indications including MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company maintains strategic partnerships with BioMarin Pharmaceutical Inc. and Endo Ventures Limited for product development and commercialization efforts.
